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INTRODUCTION 
Migraine is the second most common brain disorder (1). 
According to a report by World Health Organization, 
migraine is ranked as 19th among all diseases causing 
disability(1). Migraine and other benign recurrent 
headache disorders are major public health problems. 
They are associated with substantial personal suffering, 
disability, and societal expense (2).Moreover, Migraine is 
a common disease, and various therapeutic options are 
currently available(2). The most commonly used 
treatments for migraines include triptans, analgesics 
like NSAIDS, ergot derivatives, and antiemetics. 
However, the recent advances have raised the bar and 
options. Ubrogepant, which is an oral calcitonin 
gene-related peptide (CGRP) receptor antagonist and 
monoclonal antibiotic receptor antagonist, has been 
showing significant improvement in symptoms in recent 
trials (3, 4). Additionally, the Memantine had been 
recently introduced for the treatment of migraines (5). It 
is an uncompetitive antagonist of 
N-methyl-D-aspartate (NMDA) receptors, approved in 
the USA and many countries worldwide to treat 
migraines (5). It is currently administered twice daily as 
an immediate-release formulation, with a maximum 
recommended 20 mg/day (6). Khalid S et al. conducted 
a study which described that after treatment of 
migraine for 3 months by Memantine, the mean 
Migraine Disability Assessment Scale (MIDAS) score 
was found to be 6.72 ± 6.41 vs. 39.52 ± 21.27, 
which was noted before starting the treatment (P= 
0.00) (7). As Memantine is a relatively newer drug and 
only a few studies are available in the literature 
regarding the role of Memantine for migraine 
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ABSTRACT 
INTRODUCTION: Memantine has been suggested as a migraine prophylaxis therapy in some observational studies. 
OBJECTIVE: To determine the mean change in MIDAS score after Memantine in patients having migraine. 
SAMPLING TECHNIQUE: Non-probability, consecutive sampling.
Methods: This study was conducted in the Neurology department, Bolan Medical Complex Hospital, Quetta. January 
2017 to January 2018.  All patients in the outpatient department of Bolan medical complex hospital, Quetta, with the 
diagnosis of migraine were enrolled in the current study after informed consent.
RESULTS: A total of 68 patients with a mean age of 32.32 ± 8.44years were enrolled in the study. Gender distribution 
of the patients showed that most of the patients were female. Most of the patients had a duration of symptoms of 
>3± 2.11 years. Before starting treatment, the mean MIDAS score was age group 18-30 years 43.53 ± 13.36 and 
at the end of treatment was 9.86 ± 6.28 (P=0.005). 31-45 years age group before MIDAS score was 43.73 ± 8.83 
and treatment after MIDAS score 9.31±3.36. The difference in MIDAS scores before and after treatment was 
assessed.
CONCLUSION: The current small cohort has been effective in predicting that the use of Memantine may lead to the 
improvement in MIDAS score regarding the management of Migraines; however, large-scale studies are needed to 
validate this current study's results further.
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management (8). Recently published studies have 
emphasized the role of Memantine for migraines with 
promising results (7-9). The current study aims to observe 
the effects of Memantine on migraine management in 
a tertiary care hospital.
MATERIAL AND METHODS
After authorization from the institutional ethical board, 
all outpatient general neurology clinic patients 
diagnosed with Migraine were enrolled in the research 
study, and written consent was obtained. The inclusion 
criteria included patients with the diagnosis of 
migraine, patients with age groups 18-45. Exclusion 
criteria included patients already taking Memantine, 
patients with known psychiatric disorders, 
anti-depressants, and analgesics. Patients were 
assured regarding confidentiality for an anticipated 
better outcome. Patients fulfilling the inclusion criteria 
having migraines were assessed and were asked to fill 
MIDAS score (7-10). After that, Memantine was started as 
5mg for the 1st week, 10mg for the 2nd week, 15mg 
for the 3rd week, and 20mg for the 4th week. They 
were maintained at a dose of 20mg till the end of 3 
months. All these patients were asked to maintain a 
headache diary. At the end of 3-months of treatment, 
they were asked for a MIDAS score again. The collected 
data, including age, gender, and duration of symptoms, 
were entered and analyzed accordingly using SPSS 
version 20 through its statistical program. Mean and 
standard deviation was calculated for quantitative 
variables like age, age at the time of diagnosis of 
migraine, and MIDAS score. Frequencies and 
percentages were calculated for qualitative variables 
like gender. Mean MIDAS score was calculated both 
before and end of the treatments, and student t-test 
was applied for comparison. Effect modifiers like age, 
gender, and duration since treatment were addressed 
through stratification using an independent sample 
t-test. P-value <0.05 was considered significant.  
Results
Demographic:
A total of 68 patients were included in the study. The 
mean age of the patients was found to be 32.3 ± 8.3 
years. Patients were further categorized according to 
age groups into 2 groups (18-30 years and 31-45 
years). (Table 1) Most of the patient were female 
61.8% (N= 42) compared to male 38.2% (N= 26). 
(Table 2) Most of the patients in the current study had 
a duration of symptoms of >3 years were 45 (66.3%), 
with the mean duration of symptoms in the overall 
cohort was found as 4.4 ± 2.1 years (Table 3).
 
Outcomes:
Within the age group of 18-30 years, the  MIDAS score 
before the start of treatment was 43.53 ± 13.36, and 
at the end of treatment was 9.86 ± 6.28 (P=0.00). 
For the age group 31-45 years, the MIDAS score before 
the treatment started was 43.73 ± 8.83, and after the 
treatment, the MIDAS score was 9.31±3.36. The 
difference in MIDAS score before and after treatment 
was assessed, and it was stratified for age, gender, and 
duration of symptoms. All results are summarized in 
Table 4.
TABLE No. 1 Age DISTRIBUTION (N=68)
Abbreviations: N= Number; SD= Standard deviation
TABLE No. 2 GENDER DISTRIBUTION (n=68)
Abbreviations: N= Number
TABLE No. 3 Distribution of patients according to 
duration of symptoms (N=68)
Abbreviations: N= Number; SD= Standard deviation 
O R I G I N A L  A R T I C L E
2 7P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S V O L .  1 6  ( 1 )  J A N U A R Y - M A R C H  2 0 2 1
Age groups No. of patients % 
18-30 Years 30 43.7% 
31-45 Years 38 55.7% 
Total 68 100 
Mean ± SD 32.3 ± 8.4years 
Gender No. of patients %age 
Male 26 38.2% 
Female 42 61.8% 
Total 68 100 
Duration of symptoms No. of patients % 
<3 years 23 33.7% 
>3 years 45 66.3% 
Total 34 100 
Mean+SD 4.4 ± 2.1 years 
Table 4: Means and SD Deviation Stratification of 
Difference in MIDAS score according to age 
groups, gender and duration of symptoms
Discussion
Migraine is associated with economic burden, disability 
and poor quality of life. Despite these challenges 
majority of patients avoid or delay taking medications 
due to side effects and cost. (8-10) There are many 
options available for migraine prophylaxis with emerging 
data related to glutamate modulators. (11) Increased 
levels of glutamate in CSF of migraine patients suggest 
a pathophysiological link. Few open label studies have 
suggested Memantine (Glutamate N Methyl aspartate 
receptor antagonist) may be useful in migraine 
patients. (12-16) In one open label study of 60 patients 
more than half of patients showed 50% reduction in 
migraine pain frequency.(9) These studies are limited 
being non-randomized, unblinded with varying eligibility 
criteria and outcome measures. Use of valproate is 
associated with substantial side effects especially 
among women (13-14). Topiramate and venlafaxine are 
also associated with many limiting side effects 
especially among young migraine patients. In our study, 
Memantine was associated with minimal side effects 
and its onset of action was brief (only 3 days) as 
compared to longer periods with other migraine 
prophylaxis agents. Additionally, being a category B risk 
for pregnancy it may be suitable for pregnant migraine 
sufferers. Our study has several limitations including 
sample size , lack of randomization and unblinded 
outcome assessment. Despite these limitations this is 
first study to our knowledge in Pakistan. Larger, 
randomized controlled studies are required to prove 
efficacy of this treatment in refractory migraine 
patients.
Conclusion
In our small cohort study, the Memantine has shown an 
excellent improvement in MIDAS score regarding the 
management of Migraine; however, the current study 
results need to be explored further with well-powered 
study and randomized control trials.
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 MIDAS score before 
treatment 




18-30 Years 43.53 ± 13.36 9.86 ± 6.28 0.00 
31-45 Years 43.73 ± 8.83 9.31 ± 3.36 0.00 
Gender 
Male 50.96 ± 7.72 9.92 ± 4.85 0.00 
Female 38.83 ± 9.81 9.28 ± 4.77 0.00 
Duration since symptoms 
<3 years 49.00 ± 9.33 11.33 ± 4.83 0.00 
>3 years 40.72 ± 10.72 8.59 ± 4.60 0.00 
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